Odyssey, on second try, snags $279M in an IPO

AI Summary

Odyssey has successfully completed a $279 million initial public offering (IPO) after revising its initial filing from last year. This marks a notable rebound for the biotech firm amidst a growing trend of IPOs in the industry.

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.